<DOC>
	<DOCNO>NCT01079767</DOCNO>
	<brief_summary>RATIONALE : Temsirolimus may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well temsirolimus work treat patient advanced liver cancer cirrhosis .</brief_summary>
	<brief_title>Temsirolimus Treating Patients With Advanced Liver Cancer Cirrhosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine 3-month disease-control rate accord RECIST criterion patient advance hepatocellular carcinoma Child-Pugh class B cirrhosis . Secondary - To determine 3-month objective response rate accord RECIST criterion patient . - To determine 1-month metabolic response rate PET/CT scan patient . - To determine 1-month perfusion response rate hepatic perfusion CT scan patient . - To determine time progression patient treat drug . - To determine progression-free survival patient treated drug . - To determine overall survival patient treated drug . - To assess quality life accord QLQ-C30 QLQ-HCC18 questionnaire . - To determine clinical biological tolerance drug patient . - To determine rate m-TOR pathway activation VEGF level . - To evaluate pharmacokinetics drug select patient . OUTLINE : This multicenter study . Patients receive temsirolimus IV 30-60 minute day 1 . Treatment repeat week absence disease progression unacceptable toxicity . Patients also undergo fludeoxyglucose F 18 ( FDG ) positron emission tomography/computed tomography ( PET/CT ) scan perfusion CT scan liver baseline periodically study treatment . Patients complete quality life questionnaire ( QLC-C30 QLQ-HCC18 ) periodically . Some patient undergo blood tissue sample collection periodically pharmacological laboratory study . After completion study therapy , patient follow 24 month .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatocellular carcinoma ( HCC ) accord European Association Study Liver ( EASL ) criterion Advanced disease Must morphologically evaluable HCC accessible treatment ( e.g. , surgery , radiofrequency , chemoembolization ) benefit antiangiogenic therapy CLIP score ≤ 3 ( except patient tumor invade 50 % tumor volume ) ChildPugh cirrhosis score B7 B9 , meet follow criterion : Diagnosed clinically , biologically ( e.g. , prothrombin time , platelet , albumin ) , endoscopically ( sign portal hypertension ) morphologically ( dysmorphic liver ultrasound CT scan ) , liver biopsy Not candidate transplantation receive liver transplant PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Platelet count ≥ 50,000/mm^3 Neutrophil count ≥ 1,500/mm^3 Creatinine clearance ≥ 60 mL/min GFR ≥ 30 mL/min Serum cholesterol ≤ 350 mg/dL Triglycerides ≤ 300 mg/dL Not pregnant nursing Fertile patient must use effective contraception 2 month completion study therapy No history cancer treatment No cardiopulmonary disease impairment , include history stable unstable angina myocardial infarction No active infection except viral hepatitis No HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 week since prior inhibitor inducer Pglycoprotein , CYP3A4 , CYP3A5 At least 4 week since prior surgery , radiotherapy ( except radiotherapy bone ) , transarterial chemoembolization , immunotherapy , investigational drug HCC At least 6 month since prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>